Sara A Hurvitz, MD
Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit
UCLA Medical Center
Santa Monica, CA
Sara A Hurvitz, MD, FACP, is an Associate Professor of Medicine at the University of California, Los Angeles (UCLA), Co-Director of the Santa Monica-UCLA Outpatient Oncology Practice, Medical Director of the Clinical Research Unit of the Jonsson Comprehensive Cancer Center of UCLA, and Director of the Breast Oncology Program, Division of Hematology-Oncology at UCLA. She received her medical degree from the University of Southern California School of Medicine. Dr Hurvitz served her internship and residency at UCLA and completed a hematology-oncology fellowship at UCLA. She is board-certified in internal medicine, hematology, and medical oncology. Her research interests include the preclinical and clinical evaluation of cutting-edge targeted therapies for breast cancer, including novel therapeutic combinations. Dr Hurvitz has served as principal investigator for over 25 phase I, II, and III international breast cancer clinical trials and has presented the results of her breast cancer research at multiple national and international symposia. She has authored articles that have appeared in peer-reviewed journals, including the Journal of Clinical Oncology, Lancet Oncology, and Clinical Cancer Research. Dr Hurvitz is a member of numerous professional organizations, including the American Society of Clinical Oncology and the American Association of Cancer Research. She has also been active in community service, breast cancer advocacy, and patient education
Welcome to the second part of our post–2022-ASCO analysis of the state of affairs in the HR-positive MBC. It was not so long ago that our only options were single-agent endocrine therapy and systemic chemo. We have come a long way over the last couple of decades. Today we are asking Drs. Stephanie Graff, Sara Hurvitz, and Kevin Kalinsky to talk about how they make decisions in the clinic in selecting and sequencing treatments, specifically CDK4/6 inhibitors and the newly approved targeted therapies.